FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)
Listen to an audio podcast of the December 19, 2019 FDA Drug Safety Communication warning that serious breathing difficulties may occur in patients using seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) who have respiratory risk factors. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - January 2, 2020 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Evidence for off label prescribing - explore less, confirm more
When a new drug reaches market, the race is on to find more indications for its use - exploratory trials are set up, and positive results can lead to the off label prescriptions (eg Pregabalin for lower back pain. However, these initial indications are rarely confirmed with further, better quality, evidence.
Jonathan Kimmelman is an associate... (Source: The BMJ Podcast)
Source: The BMJ Podcast - March 23, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Evidence for off label prescribing - explore less, confirm more
When a new drug reaches market, the race is on to find more indications for its use - exploratory trials are set up, and positive results can lead to the off label prescriptions (eg Pregabalin for lower back pain. However, these initial indications are rarely confirmed with further, better quality, evidence.
Jonathan Kimmelman is an associate professor at MCgill University in Canada, thinks it's time to explore less, and confirm more - and joins us to explain why.
Read the full analysis:
http://www.bmj.com/content/360/bmj.k959 (Source: The BMJ Podcast)
Source: The BMJ Podcast - March 23, 2018 Category: General Medicine Authors: BMJ Group Source Type: podcasts
